Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorubicin in Operable/Locally Advanced Breast Cancer.

Trial Profile

Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorubicin in Operable/Locally Advanced Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record
    • 29 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Dec 2015.
    • 11 Sep 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClincialTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top